RS4651 suppresses lung fibroblast activation via the TGF-β1/SMAD signalling pathway
Author:
Funder
Beijing Municipal Health Bureau
Publisher
Elsevier BV
Subject
Pharmacology
Reference46 articles.
1. Transforming growth factor-beta: master regulator of the respiratory system in health and disease;Aschner;Am. J. Respir. Cell Mol. Biol.,2016
2. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors;Bauer;Carcinogenesis,2000
3. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis;Bollong;Proc. Natl. Acad. Sci. U.S.A.,2017
4. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue;Caminati;Eur. Respir. Rev. Off. J. Eur. Respir. Soc.,2019
5. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis;Canestaro;Chest,2016
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ziziphus spina-christi L. extract attenuates bleomycin-induced lung fibrosis in mice via regulating TGF-β1/SMAD pathway: LC-MS/MS Metabolic profiling, chemical composition, and histology studies;Biomedicine & Pharmacotherapy;2024-07
2. Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-γ/NLRP3/NF-κB and TGF-β1/Smad2/3 pathways;Scientific Reports;2024-05-15
3. Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-02-20
4. TGF-β1, pSmad-2/3, Smad-7, and β-Catenin Are Augmented in the Pulmonary Arteries from Patients with Idiopathic Pulmonary Fibrosis (IPF): Role in Driving Endothelial-to-Mesenchymal Transition (EndMT);Journal of Clinical Medicine;2024-02-19
5. A drug-responsive multicellular human spheroid model to recapitulate drug-induced pulmonary fibrosis;Biomedical Materials;2022-06-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3